{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:11:31Z","timestamp":1763727091081,"version":"3.32.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,16]],"date-time":"2016-12-16T00:00:00Z","timestamp":1481846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jsps.2016.12.006","type":"journal-article","created":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T14:01:15Z","timestamp":1482501675000},"page":"823-829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction"],"prefix":"10.1007","volume":"25","author":[{"given":"Methira","family":"Siriangkhawut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patthana","family":"Tansakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verawan","family":"Uchaipichat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2016.12.006_b0005","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jsps.2016.12.006_b0010","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/mus.20135","article-title":"Cytoskeletal myotoxicity from simvastatin and colchicine","volume":"30","author":"Baker","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jsps.2016.12.006_b0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/pds.2308","article-title":"Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population","volume":"21","author":"Bakhai","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.jsps.2016.12.006_b0020","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1517\/14740338.2012.712959","article-title":"Statin drug interactions and related adverse reactions","volume":"11","author":"Bellosta","year":"2012","journal-title":"Exp. Opin. Drug Saf."},{"key":"10.1016\/j.jsps.2016.12.006_b0025","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40264-013-0055-5","article-title":"Characterization of statin-associated myopathy case reports in Thailand using the health product vigilance center database","volume":"36","author":"Boonmuang","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.jsps.2016.12.006_b0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther."},{"key":"10.1016\/j.jsps.2016.12.006_b0035","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","article-title":"Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment","volume":"33","author":"Chatzizisis","year":"2010","journal-title":"Drug Saf."},{"key":"10.1016\/j.jsps.2016.12.006_b0040","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10557-005-6352-1","article-title":"Statin-related muscle complaints: an underestimated risk","volume":"19","author":"Corsini","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.jsps.2016.12.006_b0045","doi-asserted-by":"crossref","first-page":"61C","DOI":"10.1016\/j.amjcard.2005.12.011","article-title":"Statin safety: an assessment using an administrative claims database","volume":"97","author":"Cziraky","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jsps.2016.12.006_b0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0002-9149(02)02449-9","article-title":"Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies with Familial Hypercholesterolemia [ExPRESS FH])","volume":"90","author":"de Sauvage Nolting","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jsps.2016.12.006_b0055","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2125.2008.03345.x","article-title":"Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy","volume":"67","author":"Devold","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jsps.2016.12.006_b0060","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.amjcard.2010.07.041","article-title":"Pharmacoepidemiology safety study of fibrate and statin concomitant therapy","volume":"106","author":"Enger","year":"2010","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jsps.2016.12.006_b0065","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1023\/B:CARD.0000015861.26111.ab","article-title":"A comprehensive description of muscle symptoms associated with lipid-lowering drugs","volume":"17","author":"Franc","year":"2003","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.jsps.2016.12.006_b0070","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/CVM-2-5-205","article-title":"Withdrawal of cerivastatin from the world market","volume":"2","author":"Furberg","year":"2001","journal-title":"Curr. Control Trials Cardiovasc. Med."},{"key":"10.1016\/j.jsps.2016.12.006_b0075","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jsps.2016.12.006_b0080","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"Proposal for a new tool to evaluate drug interaction cases","volume":"41","author":"Horn","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.jsps.2016.12.006_b0085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/00002826-200209000-00008","article-title":"Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin","volume":"25","author":"Hsu","year":"2002","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.jsps.2016.12.006_b0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2710.2010.01184.x","article-title":"Simvastatin-induced myopathy, the role of interaction with diltiazem and genetic predisposition","volume":"36","author":"Hu","year":"2011","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jsps.2016.12.006_b0095","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jsps.2016.12.006_b0100","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jsps.2016.12.006_b0105","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s002280050706","article-title":"Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions","volume":"55","author":"Katoh","year":"2000","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jsps.2016.12.006_b0110","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","article-title":"Colchicine myopathy and neuropathy","volume":"316","author":"Kuncl","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2016.12.006_b0115","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.jsps.2016.12.006_b0120","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jacl.2008.10.007","article-title":"Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases","volume":"2","author":"Ming","year":"2008","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.jsps.2016.12.006_b0125","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jsps.2016.12.006_b0130","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","article-title":"Colchicine today","volume":"73","author":"Niel","year":"2006","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jsps.2016.12.006_b0135","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1291\/hypres.28.223","article-title":"Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension","volume":"28","author":"Nishio","year":"2005","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.jsps.2016.12.006_b0140","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jsps.2016.12.006_b0145","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00228-005-0972-z","article-title":"Statin-macrolide interaction risk: a population-based study throughout a general practice database","volume":"61","author":"Piacentini","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.jsps.2016.12.006_b0150","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1124\/dmd.30.11.1280","article-title":"Effects of fibrates on metabolism of statins in human hepatocytes","volume":"30","author":"Prueksaritanont","year":"2002","journal-title":"Drug. Metab. Dispos."},{"key":"10.1016\/j.jsps.2016.12.006_b0155","doi-asserted-by":"crossref","first-page":"263","DOI":"10.2165\/00002018-200528030-00007","article-title":"Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy","volume":"28","author":"Ratz Bravo","year":"2005","journal-title":"Drug Saf."},{"key":"10.1016\/j.jsps.2016.12.006_b0160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.pharmthera.2006.03.003","article-title":"Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions","volume":"112","author":"Shitara","year":"2006","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.jsps.2016.12.006_b0165","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2133\/dmpk.DMPK-13-RG-053","article-title":"Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine","volume":"29","author":"Son","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.jsps.2016.12.006_b0170","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2016.12.006_b0175","article-title":"2013 ACC\/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","author":"Stone","year":"2013","journal-title":"Circulation"},{"year":"2011","series-title":"Drug Interaction Facts","author":"Tatro","key":"10.1016\/j.jsps.2016.12.006_b0180"},{"key":"10.1016\/j.jsps.2016.12.006_b0185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2165\/00002018-200831030-00004","article-title":"Frequency and clinical relevance of drug interactions with lovastatin and simvastatin: an observational database study","volume":"31","author":"Tirkkonen","year":"2008","journal-title":"Drug Saf."},{"key":"10.1016\/j.jsps.2016.12.006_b0190","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1345\/aph.1P433","article-title":"Rhabdomyolysis in a prostate cancer patient taking Ketoconazole and Simvastatin: case report and review of the literature","volume":"45","author":"Watkins","year":"2011","journal-title":"Ann. Pharmacother."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016416301402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016416301402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:30:57Z","timestamp":1736184657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016416301402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1319016416301402"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2016.12.006","relation":{},"ISSN":["1319-0164"],"issn-type":[{"type":"print","value":"1319-0164"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of potential drug interactions in Thai patients receiving simvastatin: The causality assessment of musculoskeletal adverse events induced by statin interaction","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2016.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}